Search
Selected Filters
Displaying 41–50 of 377 news results
-
Atsena to Launch Part B of Phase 1/2 Clinical Trial for XLRS Gene Therapy
Research NewsThe Foundation is a founding investor in Atsena.
-
Research News
The company is also planning to conduct the clinical trial at sites in the EU.
-
Research News
The company has also launched a natural history study of patients to inform the planned clinical trial.
-
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
Research NewsKnown as ultevursen, the USH2A RNA therapy was licensed from ProQR.
-
Research News
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
Research NewsThe companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
Research NewsThe Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
Research NewsThe 36-participant trial will take place at multiple sites in Australia.
-
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Research NewsMerger will provide additional capital for gene therapy development.
-
MicroRNA Breakthroughs: Paving the Way for Vision Restoration
Research NewsResearchers funded by the Foundation Fighting Blindness are developing microRNA-based therapies for inherited retinal diseases, building on recent Nobel Prize-winning discoveries.
